Personalized medicine is the use of information from a patient's genotype to initiate a preventative measure against the development of a disease or condition and to select the most appropriate therapy for a disease or condition that is particularly suited to that patient. More than 99 per cent of the DNA sequence is identical among individuals. The remaining DNA is responsible for genetic diversity. Polymorphisms are common genetic variations in the human genome. TPMT gene polymorphisms are pharmacogenetic markers which enable the individualization of thiopurine drug therapy. Thiopurine drugs are widely used in the treatment of many diseases, such as acute leukaemia, different types of inflamatory , autoimmune diseases and in transplantation. Genetic polymorphisms that affect TPMT enzymatic activity are correlated with variations in sensitivity and toxicity to such drugs within individuals and lead to side effects such as myelosuppression, leukopenia. Identification of the TPMT mutant alleles will allow physicians to design the dosage of the thiopurine drugs to the genotype of the patient or to use alternatives, improving therapeutic outcome and thus will prevent the individuals with TPMT deficiency from various lethal therapeutic side effects.
Name: Sonam Chopra
Reg.No: 174111028
Guide: Mr.N.Manojkumar
Date: 6.09.12
Time: 10.30 AM
Venue: Room No: 701(B)